Your shopping cart is currently empty

Gramicidin A is a peptide antibiotic isolated from B. brevis.Gramicidin A is a highly hydrophobic channel-forming ion carrier that forms monovalent cation-permeable channels in artificial membranes.Gramicidin A induces the degradation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and reduces the growth of a mouse xenograft model of human renal cell carcinoma. Gramicidin A has antibacterial, antimalarial and hemolytic activities.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | 35 days | 35 days | |
| 5 mg | $362 | 35 days | 35 days | |
| 10 mg | $667 | 35 days | 35 days | |
| 25 mg | $1,380 | 35 days | 35 days |
| Description | Gramicidin A is a peptide antibiotic isolated from B. brevis.Gramicidin A is a highly hydrophobic channel-forming ion carrier that forms monovalent cation-permeable channels in artificial membranes.Gramicidin A induces the degradation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and reduces the growth of a mouse xenograft model of human renal cell carcinoma. Gramicidin A has antibacterial, antimalarial and hemolytic activities. |
| Targets&IC50 | Caki-1 cells:0.228 μM, 786-O cells:0.430 μM, A498 cells:0.420 μM, SN12C:0.104 μM, ACHN cells:0.783 |
| In vitro | Gramicidin A (0.1 nM-10 μM; 72 h) reduces the viability of RCC cell lines and affects cell viability comparable to Monensin.[2] Gramicidin A (1 and 10 μM, 48 or 72 h) induces nonapoptotic cell death in RCC cells.[2] Gramicidin A (0-10 μM, 24 h) depletes cellular energy and induces metabolic dysfunction in RCC cells.[2] Gramicidin A (0-1 μM, 24-72 h) reduces HIF-1α and HIF-2α protein expression and reduces HIF transcriptional activity and target gene expression (24 h).[3] |
| In vivo | Gramicidin A (0.11 mg/kg; intratumoral injection; 2 weeks; 14 days) inhibits the growth of RCC tumor xenografts with an average tumor mass reduction of approximately 40% without significant toxicity.[2] Gramicidin A (0.22 mg/kg; intratumoral injection; 3 weeks; 26 days) inhibits the growth and angiogenesis of VHL-expressing RCC tumor xenografts.[3] |
| Molecular Weight | 1882.29 |
| Formula | C99H140N20O17 |
| Cas No. | 11029-61-1 |
| Smiles | CC(C)CC(NC(=O)C(C)NC(=O)CNC(=O)C(NC=O)C(C)C)C(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCCO |
| Sequence | For-Val-Gly-Ala-D-Leu-Ala-D-Val-Val-D-Val-Trp-D-Leu-Trp-D-Leu-Trp-D-Leu-Trp-Gly-ol |
| Sequence Short | VGALAVVVWLWLWLWG |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: Soluble H2O: Slightly soluble Ethanol: Soluble |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.